Patients with advanced cancers are running out of options and time
Many of these patients have exhausted standard treatments such as surgery, radiotherapy and chemotherapy, leaving few options beyond palliative care.
5-year survival rate
Boron Neutron Capture Therapy (BNCT)
Boron compound
A boron drug (BPA) is administered and builds up in the tumour.Neutron irradiation
Only the tumour area is irradiated with neutrons.Cell destruction
The capture reaction releases particles that destroy the tumour cell.
For advanced cancer patients, survival is measured in months. BNCT offers a targeted treatment in a single day.
BOROPEPT: precision boron drugs for each cancer type
Current boron carriers (BPA) have limited tumour selectivity, uneven distribution, short retention and no molecular targeting. BOROPEPT, our patent-pending family (PCT application filed in 2026) of boron cluster–peptide conjugates, is designed to select cancer cells and can be adapted to new tumour types.
Our pipeline compounds (BOROPEPT) are in preclinical development and are not available for patient treatment.
Services for the BNCT community
Beyond our own pipeline, we put our compounds and our laboratory experience at the service of research groups, hospitals and BNCT centres.
Boron compounds: BPA and BSH
We supply compounds based on BPA (boronophenylalanine) and BSH (sodium borocaptate) to support BNCT research, clinical trials and treatments.
In vitro and in vivo studies
We test boron compounds in tumour and normal cells (in vitro) and in animal models (in vivo).
Neutron radiobiology
We have extensive experience studying the biological effects of thermal, epithermal and fast neutron beams on tumour and normal cells.
Scientific collaborations
We offer our expertise to the BNCT community through scientific collaborations and strategic alliances.
Our Mission, Vision & Values
Our mission
To develop innovative, targeted boron-based therapeutics that advance Boron Neutron Capture Therapy (BNCT), translating scientific research into new treatment opportunities for patients with difficult-to-treat cancers.
Through proprietary molecular technologies and close collaboration with academic, clinical and industry partners, we aim to address critical limitations in boron delivery and accelerate the development of next-generation cancer therapies.
Our vision
A future where targeted boron therapeutics expand the possibilities of precision oncology, making BNCT a treatment option for more patients and more types of cancer.
We aspire to become a leading innovator in boron-based drug development, connecting scientific discovery with clinical translation to address significant unmet medical needs.
Our values
- Patient-Centred Purpose
- We put patients’ unmet medical needs at the heart of our research and development.
- Scientific Rigour
- We advance through evidence, reproducibility and responsible scientific decision-making.
- Collaborative Innovation
- We bring together complementary expertise to translate research into therapeutic innovation.
- Entrepreneurial Commitment
- We turn promising science into focused development programmes with clear milestones.
- Integrity and Responsibility
- We act transparently, ethically and with accountability to patients, partners and stakeholders.
Experts in BNCT and in biotech management
Cristina Aguilera Xiol, PhD
PhD in Biomedicine. Biotech management, ex-Novartis and CNIO–Lilly Oncology partnership.
LinkedIn
Prof. Ignacio Porras Sánchez, PhD
University of Granada. Vice President of the International Society for Neutron Capture Therapy.
LinkedIn
Prof. Carmen Ruiz-Ruiz, PhD
Professor of Immunology, University of Granada. Neutron radiobiology.
Prof. Rosario Núñez Aguilera, PhD
ICMAB-CSIC, Barcelona. Boron cluster chemistry.
Maria Isabel Porras Quesada
University of Granada.
Miquel Nuez Martinez, PhD
PhD in Boron Chemistry, ICMAB Barcelona.
Advisors
José Expósito
Head of radiation oncology, Hospital Virgen de las Nieves, Granada.
Latest from Labsinlove
María Isabel Porras-Quesada wins a Fairchild Award at ICNCT-21
María Isabel Porras-Quesada, PhD student in the Labsinlove team, has received a Fairchild Award at the 21st International Congress on Neutron Capture Therapy (ICNCT-21), held in Buenos Aires, Argentina, from 25 to 30 October 2026. Named after BNCT pioneer Dr. Ralph Fairchild, the award recognises outstanding contributions to the congress by young researchers. Her work: “Feasibility Studies of the Application of Boron Neutron Capture Therapy to Pediatric Brain Tumors.” Congratulations, María Isabel!
Labsinlove at the UAB Innovation Fair 2026
Labsinlove took part in the UAB Innovation Fair 2026, the event that connects research from the Universitat Autònoma de Barcelona with companies. At the fair, our co-founder Rosario Núñez recorded the fourth episode of the UAB Research Park podcast “De la Universitat al Món”, How do we turn research into a company?, alongside Raül Aragonès, founder and CEO of AEInnova. They talk about what leads researchers to become entrepreneurs (in Catalan).
Así es Labsinlove, la empresa granadina pionera en España que combate con boro los cánceres muy agresivosES
Con sede en el Parque Tecnológico de la Salud de Granada, la empresa busca dos millones de euros para realizar los ensayos clínicos en pacientes con los cánceres de más difícil tratamiento.
Una empresa de Granada como solo hay cuatro en el mundoES
Labsinlove S.L. pone en el mercado compuestos para BNCT, una innovadora terapia para combatir cánceres de mal pronóstico. Solo hay compañías similares en Estados Unidos, Japón, China y Finlandia.
Labsinlove has been invited to join AcexHealth Accelerator
The PTS Granada Foundation hosts the fourth edition of the AcexHealth Accelerator, a programme of training, support and mentoring for Andalusian health companies and startups.
Labsinlove receives an R&D grant from Andalucía TRADE
Labsinlove was awarded an R&D incentive from Andalucía TRADE, the Andalusian Government’s business development agency, co-financed by the European Union through the European Regional Development Fund (ERDF) (grant 4IIDE2400014). The grant co-funds our R&D programme.
Labsinlove has been awarded a grant from the European Union Intellectual Property Office
EUIPO has approved a grant to Labsinlove SL which partially covers the patenting costs of the company’s IP.
Agreement between Neuboron Medtech Ltd. and Labsinlove S.L.
Neuboron Medtech, Ltd. (Nanjing, China) and Labsinlove, S.L. have signed a Memorandum of Understanding to collaborate in the development of Boron Neutron Capture Therapy.
LiL is born
Labsinlove S.L. is registered, born from the initiative of a few enthusiastic people willing to help towards a cure for the cancers of worst prognosis.
Publicly funded research
Our R&D is cofunded by the agency Andalucía Trade with EU funds (grant 4IIDE2400014) and the national Agencia Estatal de Investigación (Ministerio de Ciencia, Innovación y Universidades, grants PTQ2023-013166, DIN2024-013389 and PTQ2025-014556).
Get in touch
- Labsinlove, S.L.
Centro de Empresas PTS, Avenida del Conocimiento 41, A306. 18016 Granada, Spain - (34)-958240030
- info@labsinlove.com
Data protection. Controller: Labsinlove, S.L. Purpose: to answer your enquiry. Legal basis: your consent when you send the form. Your data will not be shared with third parties. You can access, rectify or delete your data, among other rights, by writing to info@labsinlove.com.